$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000144702819000025 Filed on August 05, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$3.061M	$653.0K	$1.244M
YoY Change	92.88%	-47.51%	19.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.250M	$8.190M	$3.780M
YoY Change	23.57%	116.67%	-17.83%
% of Gross Profit
Research & Development	$17.73M	$12.74M	$16.36M
YoY Change	7.03%	-22.11%	5.9%
% of Gross Profit
Depreciation & Amortization	$507.0K	$505.0K	$578.0K
YoY Change	2.01%	-12.63%	20.42%
% of Gross Profit
Operating Expenses	$94.09M	$21.30M	$23.29M
YoY Change	176.62%	-8.55%	13.48%
Operating Profit	-$91.03M	-$20.65M	-$22.05M
YoY Change	180.72%	-6.35%	13.14%
Interest Expense	$1.100M	$2.000K	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$4.134M	-$2.670M	$25.14M
YoY Change	-212.61%	-110.62%	1943.66%
Pretax Income	-$95.16M	-$23.32M	$3.091M
YoY Change	230.93%	-854.29%	-116.93%
Income Tax	-$12.66M	$0.00
% Of Pretax Income
Net Earnings	-$82.50M	-$23.32M	$3.091M
YoY Change	237.12%	-854.29%	-116.93%
Net Earnings / Revenue	-2695.3%	-3570.44%	248.47%
Basic Earnings Per Share	-$1.50	-$0.46	$0.01
Diluted Earnings Per Share	-$1.451M	-$0.46	$0.01
COMMON SHARES
Basic Shares Outstanding	56.85M shares	56.81M shares	55.21M shares
Diluted Shares Outstanding		56.81M shares	56.49M shares

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.10M	$95.30M	$154.9M
YoY Change	-36.55%	-38.48%	50.39%
Cash & Equivalents	$90.08M	$78.87M	$10.19M
Short-Term Investments	$0.00	$16.40M	$144.7M
Other Short-Term Assets	$1.800M	$2.800M	$1.200M
YoY Change	63.64%	133.33%	-25.0%
Inventory
Prepaid Expenses
Receivables	$2.488M	$1.531M	$1.322M
Other Receivables	$0.00	$0.00	$400.0K
Total Short-Term Assets	$94.34M	$99.58M	$157.8M
YoY Change	-34.5%	-36.88%	48.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.150M	$9.402M	$10.68M
YoY Change	-12.2%	-11.97%	-16.18%
Goodwill	$0.00	$22.47M	$22.47M
YoY Change	-100.0%	0.0%	-7.77%
Intangibles	$0.00	$43.84M	$58.65M
YoY Change	-100.0%	-25.25%	-41.03%
Long-Term Investments	$10.97M	$14.38M	$27.45M
YoY Change	-55.53%	-47.62%
Other Assets			$0.00
YoY Change			-100.0%
Total Long-Term Assets	$22.94M	$92.99M	$119.2M
YoY Change	-77.38%	-22.02%	-20.05%
TOTAL ASSETS
Total Short-Term Assets	$94.34M	$99.58M	$157.8M
Total Long-Term Assets	$22.94M	$92.99M	$119.2M
Total Assets	$117.3M	$192.6M	$277.0M
YoY Change	-52.21%	-30.48%	8.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.400M	$700.0K	$3.200M
YoY Change	-54.84%	-78.13%	-5.88%
Accrued Expenses	$7.300M	$8.000M	$5.300M
YoY Change	17.74%	50.94%	29.27%
Deferred Revenue			$974.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.817M	$8.799M	$11.54M
YoY Change	-30.4%	-23.76%	-2.86%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$24.80M	$6.600M	$10.50M
YoY Change	416.67%	-37.14%	-25.53%
Total Long-Term Liabilities	$24.80M	$6.600M	$10.50M
YoY Change	416.67%	-37.14%	-59.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.817M	$8.799M	$11.54M
Total Long-Term Liabilities	$24.80M	$6.600M	$10.50M
Total Liabilities	$33.64M	$28.10M	$38.94M
YoY Change	11.59%	-27.83%	-50.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$942.6M	-$857.3M	-$757.3M
YoY Change	20.17%	13.2%	10.07%
Common Stock	$884.6M	$884.6M	$878.2M
YoY Change	0.66%	0.73%	0.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$83.64M	$164.5M	$238.1M
YoY Change
Total Liabilities & Shareholders Equity	$117.3M	$192.6M	$277.0M
YoY Change	-52.21%	-30.48%	8.6%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$82.50M	-$23.32M	$3.091M
YoY Change	237.12%	-854.29%	-116.93%
Depreciation, Depletion And Amortization	$507.0K	$505.0K	$578.0K
YoY Change	2.01%	-12.63%	20.42%
Cash From Operating Activities	-$23.47M	-$17.61M	-$17.62M
YoY Change	77.75%	-0.1%	247.03%
INVESTING ACTIVITIES
Capital Expenditures	$255.0K	$240.0K	$425.0K
YoY Change	7.59%	-43.53%	-86.38%
Acquisitions
YoY Change
Other Investing Activities	$16.41M	$10.22M	$15.41M
YoY Change	36.64%	-33.68%	790.75%
Cash From Investing Activities	$16.16M	$9.972M	$14.98M
YoY Change	-33.73%	-33.43%	-1177.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$2.477M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$18.55M	$2.479M	$735.0K
YoY Change	4164.14%	237.28%	18275.0%
NET CHANGE
Cash From Operating Activities	-$23.47M	-$17.61M	-$17.62M
Cash From Investing Activities	$16.16M	$9.972M	$14.98M
Cash From Financing Activities	$18.55M	$2.479M	$735.0K
Net Change In Cash	$11.21M	-$5.097M	-$2.268M
YoY Change	-4.51%	124.74%	-64.91%
FREE CASH FLOW
Cash From Operating Activities	-$23.47M	-$17.61M	-$17.62M
Capital Expenditures	$255.0K	$240.0K	$425.0K
Free Cash Flow	-$23.73M	-$17.85M	-$18.05M
YoY Change	76.51%	-1.12%	120.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2341000	USD
CY2019Q2	abus	Accrued Payroll Current AccruedPayrollCurrent	4159000	USD
CY2018Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2716000	USD
CY2019Q2	abus	Accrued Research And Development AccruedResearchAndDevelopment	2528000	USD
CY2018Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-504000	USD
CY2018Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-34000	USD
CY2019Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	47000	USD
CY2019Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	230000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	479000	USD
CY2019Q2	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	141000	USD
	abus	Fixed Lease Cost FixedLeaseCost	600000	USD
CY2018Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	193000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-655000	USD
CY2019Q2	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	130000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	255000	USD
CY2019Q2	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	2	lease
	abus	Strightline Fixed Lease Cost StrightlineFixedLeaseCost	600000	USD
CY2019Q2	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56850172	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9429000	USD
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7940000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3192000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48170000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	5477000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48244000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48084000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53738000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1510000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1862000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1665000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3915000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28000000	shares
CY2018Q4	us-gaap	Assets Assets	227905000	USD
CY2019Q2	us-gaap	Assets Assets	192570000	USD
CY2019Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	685000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1431000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	129229000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	99583000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	130000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	255000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9769000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1531000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2019Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3381000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	566000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-779000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36942000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	78872000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7090000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8105000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	193000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-655000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54292000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12461000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10193000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36942000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83969000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78872000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2268000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44099000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5097000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	41930000	USD
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2019Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55518800	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56850172	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55518800	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56850172	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	879405000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	884623000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3091000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-926000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14338000	USD
CY2019Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2762000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23367000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46640000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	645000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q2	us-gaap	Depreciation Depreciation	578000	USD
	us-gaap	Depreciation Depreciation	1180000	USD
CY2019Q2	us-gaap	Depreciation Depreciation	505000	USD
	us-gaap	Depreciation Depreciation	1014000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	578000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1180000	USD
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	505000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1014000	USD
CY2018Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2541000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	4877000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2018Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-361000	USD
CY2019Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22224000	USD
CY2019Q2	us-gaap	Equity Method Investments EquityMethodInvestments	14377000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-359000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-885000	USD
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	60000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	68000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-361000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-926000	USD
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	57000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	95000	USD
CY2018Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	24884000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	24884000	USD
CY2019Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2018Q2	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q2	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-3334000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	623000	USD
CY2018Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	921000	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-7985000	USD
CY2018Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	11000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3775000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7444000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8189000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12601000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	22471000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	22471000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3091000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14338000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23315000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46566000	USD
CY2018Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2019Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3334000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7985000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3266000	USD
CY2019Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	888000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1858000	USD
CY2018Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	603000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	920000	USD
CY2019Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	608000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	100000	USD
CY2018Q2	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
CY2019Q2	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-746000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1768000	USD
CY2019Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019Q2	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-95000	USD
CY2018Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-222000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-907000	USD
CY2019Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1616000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-759000	USD
CY2018Q2	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	61000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1090000	USD
CY2019Q2	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-640000	USD
	us-gaap	Restructuring Charges RestructuringCharges	-149000	USD
	us-gaap	Restructuring Costs RestructuringCosts	395000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	104000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	2000	USD
	us-gaap	Interest Expense InterestExpense	14000	USD
CY2018Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	805000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1563000	USD
CY2019Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	606000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1206000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4984000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2038000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	598000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	581000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	677000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	657000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	433000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1345000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	27671000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	28104000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227905000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	192570000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11239000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8799000	USD
CY2018Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	735000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55102000	USD
CY2019Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2479000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5015000	USD
CY2018Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14980000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60686000	USD
CY2019Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9972000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	71005000	USD
CY2018Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17622000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37589000	USD
CY2019Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17605000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34185000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	3091000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14338000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-23251000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23315000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-46566000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	550000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19215000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26077000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52043000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25137000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26113000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2800000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6980000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	23290000	USD
	us-gaap	Operating Expenses OperatingExpenses	43131000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	21168000	USD
	us-gaap	Operating Expenses OperatingExpenses	40918000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-22046000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40451000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20515000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39586000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3639000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	376000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3263000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4100000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2901000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3200000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.087
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	309000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-52000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-74000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52000	USD
CY2018Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	60015000	USD
CY2019Q2	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	840000	USD
CY2018Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	425000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	673000	USD
CY2019Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	240000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	271000	USD
CY2018Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018Q2	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2541000	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4877000	USD
CY2019Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2762000	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	5477000	USD
CY2018Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	126136000	USD
CY2019Q2	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	131613000	USD
CY2018Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2019Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3181000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2770000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2477000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4725000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2019Q2	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2018Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2019Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	USD
CY2018Q2	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	15403000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
CY2019Q2	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	10210000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	71265000	USD
CY2018Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	735000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	838000	USD
CY2019Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	290000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10145000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9402000	USD
CY2018Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2019Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16356000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30305000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12740000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27452000	USD
	us-gaap	Restructuring Charges RestructuringCharges	4700000	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	2581000	USD
	us-gaap	Restructuring Charges RestructuringCharges	4202000	USD
CY2019Q2	us-gaap	Restructuring Charges RestructuringCharges	-266000	USD
CY2018Q2	us-gaap	Restructuring Costs RestructuringCosts	395000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-857264000	USD
CY2018Q2	us-gaap	Revenues Revenues	1244000	USD
	us-gaap	Revenues Revenues	2680000	USD
CY2019Q2	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	1331000	USD
CY2019Q2	us-gaap	Restructuring Reserve RestructuringReserve	342000	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1331000	USD
CY2019Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	342000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805221000	USD
CY2019Q2	us-gaap	Revenues Revenues	653000	USD
	us-gaap	Revenues Revenues	1332000	USD
CY2018Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2661000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3616000	USD
CY2019Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3784000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5306000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	87675000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	16410000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	66265000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2248000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2477000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	735000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	288000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	232418000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	238072000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	181209000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	164466000	USD
	us-gaap	Sublease Income SubleaseIncome	20000	USD
	us-gaap	Sublease Income SubleaseIncome	200000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	200000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56487220	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55149674	shares
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56805583	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56275795	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55211294	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55149674	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56805583	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56275795	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. These include AB-506, the Company's oral capsid inhibitor currently in a Phase 1a/1b clinical trial, AB-729, the Company's second generation RNA interference ("RNAi") therapeutic candidate also currently in a Phase 1a/1b clinical trial, and AB-452, the Company's lead oral HBV RNA destabilizer candidate currently in pre-clinical testing. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001447028-19-000025-index-headers.html	Edgar Link	pending
0001447028-19-000025-index.html	Edgar Link	pending
0001447028-19-000025.txt	Edgar Link	pending
0001447028-19-000025-xbrl.zip	Edgar Link	pending
abus-20190630.xml	Edgar Link	completed
abus-20190630.xsd	Edgar Link	pending
abus-20190630_cal.xml	Edgar Link	unprocessable
abus-20190630_def.xml	Edgar Link	unprocessable
abus-20190630_lab.xml	Edgar Link	unprocessable
abus-20190630_pre.xml	Edgar Link	unprocessable
arbutusq22019.htm	Edgar Link	pending
exhibit105mcelhaughexeceea.htm	Edgar Link	pending
exhibit109collieroptionagr.htm	Edgar Link	pending
exhibit20-3revised2016plan.htm	Edgar Link	pending
exhibit201redactedroyaltym.htm	Edgar Link	pending
exhibit2022016omnibusshare.htm	Edgar Link	pending
exhibit311q22019.htm	Edgar Link	pending
exhibit312q22019.htm	Edgar Link	pending
exhibit321q22019.htm	Edgar Link	pending
exhibit322q22019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbvpipelinevaug1final.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2019 Q3 Form 10-Q Financial Statement

#000144702819000025 Filed on August 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2019 Q3 Form 10-Q Financial Statement

#000144702819000025 Filed on August 05, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus